CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published ahead of print on October 18, 2006
Clin J Am Soc Nephrol 2: 68-73, 2007
© 2007 American Society of Nephrology
doi: 10.2215/CJN.01280406

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.01280406v1
2/1/68    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Passalent, L.
Right arrow Articles by Gardam, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Passalent, L.
Right arrow Articles by Gardam, M.

Diagnosis

Detecting Latent Tuberculosis Infection in Hemodialysis Patients: A Head-to-Head Comparison of the T-SPOT.TB Test, Tuberculin Skin Test, and an Expert Physician Panel

Laura Passalent*, Kamran Khan{dagger},{ddagger}, Robert Richardson§, Jun Wang{ddagger}, Helen Dedier*, and Michael Gardam*,||

* Infection Prevention and Control Unit and Divisions of § Nephrology and || Infectious Diseases, University Health Network, and {dagger} Division of Infectious Diseases and {ddagger} Centre for Research on Inner City Health, St. Michael’s Hospital, Toronto, Ontario, Canada

Address correspondence to: Dr. Michael Gardam, 200 Elizabeth Street, 3ES-428, Toronto General Hospital, Toronto, ON, Canada, M5G 2C4. Phone: 416-340-3758; Fax: 416-340-5047; E-mail: michael.gardam{at}uhn.on.ca

Current guidelines advocate screening hemodialysis patients for latent tuberculosis infection; however, the tuberculin skin test (TST) is believed to be insensitive in this population. This study compared the diagnostic utility of the TST with that of an IFN-{gamma} assay (T-SPOT.TB) and the clinical consensus of an expert physician panel. A total of 203 patients with ESRD were evaluated for latent tuberculosis infection with the TST, T-SPOT.TB test, and an expert physician panel. Test results were compared with respect to their association with established tuberculosis risk factors. Tuberculosis infection, as estimated by the tuberculin test, T-SPOT.TB test, and expert physician panel, was detected in 12.8%, 35.5, and 26.1 of patients respectively. Among patients with a history of active tuberculosis and radiographic markers of previous infection, 78.6 and 72.7% had positive T.SPOT.TB results, compared with 21.4 and 18.2% who had positive tuberculin tests. The physician panel unanimously declared infection in these two groups. On multivariate analysis, a positive T-SPOT.TB test was associated with a history of active tuberculosis, radiographic markers of previous infection, and birth in an endemic country, whereas a physician panel diagnosis also was associated with a history of previous tuberculosis contact. The TST is insensitive in hemodialysis patients and is not recommended to be used in isolation to diagnose latent tuberculosis infection. It is suggested that a combination of T-SPOT.TB testing and medical assessment may be the most accurate screening method.




This article has been cited by other articles:


Home page
CJASNHome page
K. L. Winthrop, M. Nyendak, H. Calvet, P. Oh, M. Lo, G. Swarbrick, C. Johnson, D. A. Lewinsohn, D. M. Lewinsohn, and G. H. Mazurek
Interferon-{gamma} Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1357 - 1363.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
R. Dinser, M. Fousse, U. Sester, K. Albrecht, M. Singh, H. Kohler, U. Muller-Ladner, and M. Sester
Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-{alpha} blocking drugs using a novel flow-cytometric interferon-{gamma} release assay
Rheumatology, February 1, 2008; 47(2): 212 - 218.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Nephrology.